Wall Street analysts expect that Sotera Health (NYSE:SHC) will report sales of $236.45 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Sotera Health’s earnings, with estimates ranging from $234.90 million to $238.91 million. Sotera Health posted sales of $216.85 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 9%. The business is scheduled to announce its next quarterly earnings results on Tuesday, March 8th.
According to Zacks, analysts expect that Sotera Health will report full-year sales of $926.68 million for the current fiscal year, with estimates ranging from $925.10 million to $929.14 million. For the next fiscal year, analysts expect that the company will report sales of $1.02 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Sotera Health.
Sotera Health (NYSE:SHC) last issued its earnings results on Wednesday, November 10th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.02. The firm had revenue of $226.16 million during the quarter, compared to the consensus estimate of $222.55 million. Sotera Health had a net margin of 4.10% and a return on equity of 35.74%.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. bought a new stake in Sotera Health during the third quarter worth $26,000. Spire Wealth Management bought a new stake in Sotera Health during the third quarter worth $29,000. Allworth Financial LP bought a new stake in Sotera Health during the third quarter worth $35,000. Mitsubishi UFJ Trust & Banking Corp bought a new stake in Sotera Health during the third quarter worth $86,000. Finally, SG Americas Securities LLC bought a new stake in Sotera Health during the second quarter worth $113,000. Institutional investors and hedge funds own 86.95% of the company’s stock.
Shares of Sotera Health stock traded up $0.10 on Thursday, hitting $21.91. The company had a trading volume of 657,454 shares, compared to its average volume of 987,015. The firm has a market capitalization of $6.20 billion and a P/E ratio of 182.60. Sotera Health has a twelve month low of $21.18 and a twelve month high of $30.38. The company has a debt-to-equity ratio of 3.39, a current ratio of 2.52 and a quick ratio of 2.46. The stock has a 50-day moving average of $25.20 and a 200-day moving average of $24.38.
Sotera Health Company Profile
Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.
Read More: Sell-Side Analysts
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.